Camlin Fine Sciences , a key player in the Indian chemical sector, has successfully completed the postal ballot process for the re-appointment of its Independent Director, with shareholders overwhelmingly approving the proposal with official results now confirmed.

Postal Ballot Results

The postal ballot voting concluded on December 13, 2025, with shareholders approving the re-appointment of Mr. Mahabaleshwar G. Palekar as Non-Executive Independent Director for a second five-year term. The official voting results demonstrate exceptional shareholder confidence in the leadership decision.

Director Re-appointment Details

Mr. Mahabaleshwar G. Palekar (DIN: 02455892) has been re-appointed as Non-Executive Independent Director for a second term of five consecutive years, commencing from December 24, 2025, to December 23, 2030. The appointment was processed through remote e-voting facility provided by National Securities Depository Limited (NSDL).

Category-wise Voting Breakdown

The detailed voting results across different shareholder categories show strong support across all segments:

Voting Process and Compliance

The postal ballot process was conducted in accordance with Section 108 of the Companies Act, 2013, and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. S.J. Ranade, Partner of JHR Associates, served as the scrutinizer for the voting process and submitted the official scrutinizer report on December 15, 2025.

Corporate Governance Initiatives

The overwhelming approval of Mr. Palekar's re-appointment reflects strong shareholder confidence in the company's leadership and governance structure, supporting Camlin Fine Sciences' long-term strategic objectives. The company continues to maintain high standards of corporate governance with transparent voting processes and comprehensive disclosure requirements.

Camlin Fine Sciences Limited (CFSL) has issued a corrigendum to its postal ballot notice dated September 29, 2025, providing additional clarifications requested by the BSE and NSE regarding a proposed preferential issue of equity shares. This move comes as part of CFSL's strategic acquisition of a majority stake in French company Vinpai.

Key Details of the Preferential Issue

CFSL plans to issue 41,06,181 equity shares at ₹247.69 per share as consideration for acquiring a 78.68% stake in Vinpai through a share swap arrangement. The total consideration for the acquisition is €98.03 million, equivalent to approximately ₹101.71 crore.

Vinpai: A Strategic Acquisition

Vinpai, founded in 2011, is an 'ingredien'tech' company specializing in algae, plant, mineral, and fiber-based functional ingredients. The company offers natural alternatives to chemical additives for the food, cosmetics, and nutraceutical industries. In 2024, Vinpai generated revenues of €9.2 million, with over 70% from exports to more than 36 countries.

Share Swap Details

The following table outlines the share swap arrangement:

Impact on Shareholding

Post-issue, the new shareholders from Vinpai will collectively hold 2.10% of CFSL's expanded share capital. The promoter and promoter group holding is expected to decrease slightly from 49.08% to 47.08%, while public shareholding will increase from 50.92% to 52.92%.

Strategic Rationale

The acquisition of Vinpai is expected to enhance CFSL's product offerings, fostering innovation and competitiveness in the global market. It opens up new product ranges in the natural space and provides access to exciting markets, potentially leading to expansion of revenues and margins.

Regulatory Compliance

CFSL has obtained a valuation report from Sundae Capital Advisors Private Limited, an independent registered valuer, to comply with SEBI regulations. The company has also granted members who have already voted an opportunity to update their votes based on the additional information provided in the corrigendum, with submissions accepted until October 29, 2025.

This strategic move by Camlin Fine Sciences Limited represents a significant step towards expanding its presence in the natural ingredients market, potentially strengthening its position in the global food and nutraceutical industry.